11.30.-1
Alexion
1Q Revenues: $566.6 million (+67%)
1Q Earnings: $159.4 million (+94%)
Comments: Solaris sales were $566.6 million, up 67%, and included reimbursement of prior year shipments related to an agreement with the French government of $87.8 million. Sales also include additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). R&D expenses were $191.5 million, up from $74.5 in 1Q13.
1Q Revenues: $566.6 million (+67%)
1Q Earnings: $159.4 million (+94%)
Comments: Solaris sales were $566.6 million, up 67%, and included reimbursement of prior year shipments related to an agreement with the French government of $87.8 million. Sales also include additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). R&D expenses were $191.5 million, up from $74.5 in 1Q13.